Publications

Publications

1. Zarin DA, Goodman SN, Kimmelman J. Harms from uninformative clinical trials. JAMA. 2019;322(9):813-814. doi:10.1001/jama.2019.9892
2. Hartman D, Heaton P, Cammack N, Hudson I, Dolley S, Netsi E, Norman T, Mundel T. Clinical trials in the pandemic age: What is fit for purpose? Gates Open Research. 2020;4. https://gatesopenresearch.org/articles/4-58
3. Dolley, S, D Hartman, T Norman, and I Hudson. Target Policy Profile (TPoP) Version 2 Design Analyze Communicate (DAC), Bill & Melinda Gates Foundation 2020. May.https://doi.org/10.48060/tghn.2.
4. Bugin K, Woodcock J. Trends in COVID-19 Therapeutic Clinical Trials. Nature. 2021 Feb BioBusiness Briefs. doi: https://doi.org/10.1038/d41573-021-00037-3 Supplementary information
5. Hutchinson N, Moyer H, Zarin DA, Kimmelman J. The proportion of randomized controlled trials that inform clinical practice. (2022) eLife 11:e79491: https://doi.org/10.7554/eLife.79491  
6. Uninformative Research: The global health crisis you’ve never heard of. Ideas Blog. https://www.gatesfoundation.org/ideas/articles/deworm3-clinical-trials-show-the-value-of-informed-research
7. Saidu Y, Ben Bachire H, Frambo A et al. Health policy making process in Cameroon: a case for the utilization of the Target Policy Profile [version 1; peer review: 2 approved with reservations]. Gates Open Res 2022, 6:68 (https://doi.org/10.12688/gatesopenres.13580.1)
8. Foundation, B. &. M. G. (2023, September 8). Design, Analyze, Communicate  (DAC) Assessment Tool. https://doi.org/10.31219/osf.io/b8n73
9. Stevens G, Dolley S, Mogg R, Connor JT. A template for the authoring of statistical analysis plans. Contemp Clin Trials Commun. 2023 Jun 9;34:101100. doi: 10.1016/j.conctc.2023.101100. PMID: 37388218; PMCID: PMC10300078.  https://www.sciencedirect.com/science/article/pii/S2451865423000467
10. Burford, Belinda & Norman, Thea & Dolley, Shawn. (2023). Scientific Review of Protocols to Enhance Informativeness of Global Health Clinical Trials. https://doi.org/10.21203/rs.3.rs-3717747/v1
11. Dolley S, Norman TC, McNair D, Hartman D. A Maturity Model for the Scientific Review of Clinical Trial Designs and Their Informativeness. Trials (2024) 25: 271. https://rdcu.be/dFfsz.
12. Dolley, S. A Novel Feasibility Study Design Enabling Informative Clinical Trials in Low Resource Settings: the Pop-Up Prevalence study with Private Ethics (PUPPE). Preprints 2024, 2024010020. https://doi.org/10.20944/preprints202401.0020.v1
13. S Dolley, C Miller, P Quach, T Norman Recent cross-sectional prevalence studies in sub-Saharan Africa for communicable, maternal, neonatal, and nutritional diseases and conditions: a scoping review. medRxiv 2023.12.24.23300511;https://doi.org/10.1101/2023.12.24.23300511
14. Arianna Rubin , List Kellie , Roll Amy , Gwayi-Chore Marie-Claire , Dolley Shawn , Schünemann Holger J. , Norman Thea C. , Walson Judd L. Participatory development of a target policy profile to support soil-transmitted helminth elimination. Frontiers in Health Services. 2024 (3). DOI=10.3389/frhs.2023.1310694. https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2023.1310694
15. Wood TA and McNair D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness [version 1; peer review: 1 approved with reservations]. Gates Open Res 2023, 7:56 (https://doi.org/10.12688/gatesopenres.14416.1)